Price$5.72-0.01 (-0.17%)
02:30 PM07:45 PM
News · 26 weeks34-60%
2025-12-072026-05-31
Mix2590d
- SEC Filings12(48%)
- Insider5(20%)
- Earnings4(16%)
- Other2(8%)
- Analyst2(8%)
Latest news
25 items- SECSEC Form S-8 filed by LENSAR Inc.S-8 - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events8-K - LENSAR, Inc. (0001320350) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by LENSAR Inc.SCHEDULE 13G/A - LENSAR, Inc. (0001320350) (Subject)
- SECSEC Form 144 filed by LENSAR Inc.144 - LENSAR, Inc. (0001320350) (Subject)
- INSIDERChief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,739 shares, decreasing direct ownership by 0.77% to 354,330 units (SEC Form 4) (tax liability)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4) (for withholding tax)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,350 shares, decreasing direct ownership by 0.77% to 174,609 units (SEC Form 4) (tax withholding)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERPrincipal Accounting Officer Wong Kendra covered exercise/tax liability with 864 shares, decreasing direct ownership by 2% to 43,415 units (SEC Form 4) (for tax liability)4 - LENSAR, Inc. (0001320350) (Issuer)
- SECSEC Form 10-Q filed by LENSAR Inc.10-Q - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® Reports First Quarter 2026 Results and Provides Business Update7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre
- SECAmendment: SEC Form 10-K/A filed by LENSAR Inc.10-K/A - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® to Report First Quarter 2026 Results on May 8, 2026ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra
- SECLENSAR Inc. filed SEC Form 8-K: Leadership Update8-K - LENSAR, Inc. (0001320350) (Filer)
- ANALYSTLENSAR upgraded by Lake Street with a new price targetLake Street upgraded LENSAR from Hold to Buy and set a new price target of $10.00
- SECSEC Form 10-K filed by LENSAR Inc.10-K - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh
- INSIDERSEC Form 4 filed by Staab Thomas R Ii4 - LENSAR, Inc. (0001320350) (Issuer)
- ANALYSTLENSAR upgraded by BTIG Research with a new price targetBTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00
- SECLENSAR Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure8-K - LENSAR, Inc. (0001320350) (Filer)
- PRAlcon and LENSAR, Inc. Agree to Terminate Merger AgreementAlcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d
- PRLENSAR® Announces Termination of Merger Agreement with Alcon Research, LLCORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli
- SECAmendment: LENSAR Inc. filed SEC Form 8-K: Other Events8-K/A - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Other Events8-K - LENSAR, Inc. (0001320350) (Filer)
LNSR FAQ
6 questionsWhat does LENSAR Inc. do?
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.Where does LNSR stock trade?
LENSAR Inc. (LNSR) is listed on NASDAQ.What sector and industry is LNSR in?
LENSAR Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about LNSR?
LENSAR Inc. has had 3 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1000.00 price target on 2026-04-01. Recent price targets range from $1000.00 to $1500.00.What companies are similar to LNSR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare LNSR side-by-side with any of them on Quantisnow.How can I track LNSR on Quantisnow?
Quantisnow aggregates LENSAR Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LNSR to receive live email and push alerts on every new disclosure.